Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread II -- Ignore unavailable to you. Want to Upgrade?

To: SirRealist who wrote (5612)	8/6/2001 10:29:07 AM
From: SirRealist	Read Replies (1) \| Respond to of 9026

QMDC broke above 52 wk high.

To: SirRealist who wrote (5612)	8/6/2001 10:42:18 AM
From: lexi2004	Read Replies (1) \| Respond to of 9026

CLPA up on news... Monday August 6, 8:16 am Eastern Time Press Release SOURCE: Cell Pathways Cell Pathways Advances Second SAAND Compound, CP461, to Phase II Testing HORSHAM, Pa.--(BW HealthWire)--Aug. 6, 2001--Cell Pathways, Inc., (Nasdaq:CLPA - news) today announced it has initiated three pilot Phase II studies of CP461, the Company's second selective apoptotic anti-neoplastic drug (SAAND). These Phase IIa human clinical trials will investigate the safety and efficacy of CP461 as a single agent in patients with chronic lymphocytic leukemia (CLL), renal cell (kidney) carcinoma, and hormone-refractory prostate cancer. In each of these open-label studies, fourteen to nineteen patients will be evaluated for an objective response to CP461 treatment by measuring tumor size or tumor burden. Patients will be tracked for a minimum of three months. Assuming positive results from one or more of these Phase IIa studies, the Company plans to expand enrollment into larger Phase IIb trial(s). ``These studies mark the start of our Phase II clinical development program for CP461, which plans to include studies investigating the compound as both a single agent for the treatment of cancer and in combination with other leading chemotherapeutic drugs,'' said Robert E. Bellet, M.D., Cell Pathways' senior vice president of clinical and regulatory affairs. ``The preclinical results with CP461 have been very encouraging. Cell culture and animal studies have suggested that CP461 may have substantial potency as an anti-cancer agent. Also, CP461's pro-apoptotic effects in cell culture (or the triggering of programmed cell death in tumor cells by inhibiting certain cyclic GMP phosphodiesterases) are rapid in onset. ``We plan to investigate CP461 in a number of clinical cancer indications,'' Dr. Bellet continued. ``We chose CLL, renal cancer and hormone-refractory prostate cancer based on earlier observations that these tumor types either over-express the cyclic GMP phosphodiesterases targeted by CP461, or demonstrate evidence of tumor cell sensitivity to CP461 in cultured cancer cell lines, animals studies, or primary cultures of cancer cells from affected patients.'' ``CLL, renal cancer and hormone refractory prostate cancer are all cancers where the current treatment options are limited and new therapies are sorely needed. Positive results from studies in any of these diseases may present opportunities for the accelerated clinical development of CP461,'' said Robert Towarnicki, chairman and chief executive officer of Cell Pathways. CP461 is a second-generation SAAND compound, designed to treat cancer by selectively triggering programmed cell death, or apoptosis, in precancerous and cancer cells but not normal cells. Data from a Phase I safety study of CP461 presented earlier this year showed that the drug was rapidly absorbed when orally administered and was well tolerated by patients. Cell Pathways, Inc., headquartered in Horsham, Pennsylvania, is a development stage pharmaceutical company focused on the research, development and commercialization of novel and unique medications to prevent and treat cancer. For additional information on Cell Pathways, Inc., visit the company's web site at cellpathways.com.